A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Exclusion Criteria

• •Participants who have previously received anti-cluster of differentiation (CD) 20s (including ocrelizumab) less than 2 years before screening
• •Participants who have previously received anti-CD20s (including ocrelizumab) more than 2 years before screening if one of the following conditions is met: B-cell count is below lower limit of normal (LLN), or the discontinuation of the treatment was due to safety reasons
• •History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
• •History of cancer, including hematologic malignancy and solid tumors, within 10 years of screening
• •Immunocompromised state
• •Sensitivity or intolerance to any ingredient (including excipients) of ocrelizumab
• •History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
• •Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
• •Significant, uncontrolled disease, such as cardiovascular, pulmonary, renal, hepatic, endocrine or gastrointestinal, or any other significant disease that may preclude participation in the study
• •Lack of peripheral venous access
• •Previous treatment with cladribine, atacicept, and alemtuzumab
• •Any previous treatment with bone marrow transplantation and hematopoietic stem cell transplantation
• •Any previous history of transplantation or anti-rejection therapy
• •Positive screening tests for active, latent, or inadequately treated hepatitis B virus (HBV)